𝔖 Bobbio Scriptorium

✦ LIBER ✦

Accrual to National Cancer Institute—Sponsored Non–Small-Cell Lung Cancer Trials: Insights and Contributions From the CCOP Program

✍ Scribed by Alan P. Lyss; Rogerio C. Lilenbaum

Book ID: 115076749
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 95 KB
Volume: 10
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2009.n.077

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Corrigendum to: “Compliance with post-op

Corrigendum to: “Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of National Cancer institute of Canada and intergroup trial JBR.10 and a review of the literature” [Lung Cancer 47 (2005) 385–394]

✍ Alam, Naveed; Shepherd, Frances A.; Winton, Timothy; Graham, Barbara; Johnson, D 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Phase I study of paclitaxel (TaxolR) and

Phase I study of paclitaxel (TaxolR) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Smoking History and Epidermal Growth Fac

Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21

✍ Gary M. Clark; Denni M. Zborowski; Pedro Santabárbara; Keyue Ding; Marlo Whitehe 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 166 KB

Bexarotene in Combination with Chemother

Bexarotene in Combination with Chemotherapy Fails to Prolong Survival in Patients with Advanced Non–Small- Cell Lung Cancer: Results from the SPIRIT I and II Trials

✍ Preeta Tyagi; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 457 KB

92 POSTER Effects of AZD2171 on pharmaco

92 POSTER Effects of AZD2171 on pharmacokinetics (PK) of carboplatin (C) and paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; W. Zhang; S. Lauri; A. Arnold; I. Gauthier; G. Goss; P. Ellis; F. Sheph 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB